WO1993000940A1 - Appareil pour faire penetrer des medicaments dans des globules rouges - Google Patents
Appareil pour faire penetrer des medicaments dans des globules rouges Download PDFInfo
- Publication number
- WO1993000940A1 WO1993000940A1 PCT/FR1992/000623 FR9200623W WO9300940A1 WO 1993000940 A1 WO1993000940 A1 WO 1993000940A1 FR 9200623 W FR9200623 W FR 9200623W WO 9300940 A1 WO9300940 A1 WO 9300940A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lysis
- resealing
- suspension
- module
- washing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/369—Temperature treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/366—General characteristics of the apparatus related to heating or cooling by liquid heat exchangers
Definitions
- the present invention relates to a device allowing the implementation of the so-called “lysis-resealing” technique which makes it possible to incorporate active principles into red blood cells.
- the primary compartment of a first dialysis element is continuously fed with an aqueous suspension of erythrocytes, the secondary compartment containing an aqueous solution hypotonic with respect to the suspension of erythrocytes in order to lyse erythrocytes.
- the erythrocyte lysate is then in contact with the substance having a biological activity and in order to reseal the membrane of the erythrocytes, the osmotic and / or oncotic pressure of the erythrocyte lysate is increased after it is brought into contact with the substance having biological activity.
- resealing is carried out in a separate container although it is possible, as described in the patent, to practice resealing using successively two dialysis coils. More precisely in this type of process, the globular pellet is obtained by centrifugation and decantation of the plasma, which is stored at 4 ° C. for treatment. The red blood cells undergo a first series of washes. The first wash in physiological serum makes it possible to obtain a globular concentrate from which the "buffy coat" (white blood cells, platelets) is eliminated. The concentrate of red blood cells is then brought into contact with IHP (inositol hexaphosphate) for example during the following two washes.
- IHP inositol hexaphosphate
- the red blood cell In a hypotonic environment, the red blood cell swells to a volume which can be equal to 175% of its initial value (ROPARS et Coll., 1986). It is at this stage that pores of a few hundred angstroms appear. There is then an exchange between the extra-cellular and intra-cellular media, in particular for the substance to be internalized. After addition of a hypertonic solution in the hemolysate, the isotonicity is restored, the pores close and trap the IHP for example in the red blood cell. This is followed by an incubation phase in a regenerative solution, necessary for charged red blood cells to find the same permeability characteristics as those of initial red blood cells. After resealing, the red blood cells undergo a second series of washes. The first two washes use a physiological saline solution: they make it possible to eliminate unresealed red blood cells.
- the red blood cells are then returned to autologous plasma at a physiological hematoc ⁇ te allowing the transfusion.
- the transformed blood unit is made up of red blood cells with improved oxyphonic properties, the morphological and physiological characteristics of which are close to unprocessed red blood cells.
- the implementation of the lysis-resealing process allows the incorporation of a large number of active principles into red blood cells, which can be reinjected into the same patient or into different patients.
- the incorporation of IHP into erythrocytes makes it possible to modify the affinity constant of hemoglobin for oxygen.
- the present invention relates to a device intended to allow the incorporation of one or more substances with biological activity in red blood cells by the lysis-resealing technique, characterized in that it comprises
- a lysis and resealing unit consisting of a lysis module at a temperature below 10 ° C and a resealing module at a temperature above 20 ° C, all of the elements of the lysis unit and resealing coming into contact with the erythrocyte suspension being designed for single use. It should be understood that "designed for single use”, even if the elements are intended to be reused, they will only be after sterilization and / or viral inactivation but will be designed as single-use elements, that is to say that can easily be set up and dismantled and of low cost.
- the lysis module A is constituted
- a removable assembly preferably for single use, comprising a dialysis cartridge (9) capable of being fixed on the inlet of the lysis buffer to supply one of the compartments, the other compartment of the cartridge being connected at the venous end to a container (6) intended for warming up the suspension of erythro ⁇ cytes, and at the arterial end to a storage container (11).
- the resealing module consists of a set of elements enabling the module to be maintained at a determined temperature 0, preferably 37 ° C., and a removable assembly, preferably for single use and comprising upstream towards the 'downstream, a container (22) intended to ensure the temperature rise of the suspension connected to a container (26) comprising a supply of resealing solution (28).
- All of these modules include a pump allowing the entry of the erythrocyte suspension into the lysis module, a pump allowing the exit of the erythrocyte suspension from the resealing module, and an intermediate pump ensuring circulation between the lysis module and the resealing module.
- These pumps are preferably peristaltic pumps, which avoid contact with the suspension.
- the device also preferably comprises, in front of the resealing unit, a tube for supplying a solution of an active principle to be internalized, for example ATP (adenosine triphosphate).
- an active principle to be internalized for example ATP (adenosine triphosphate).
- ATP adenosine triphosphate
- the containers intended to ensure the temperature of the suspensions are preferably plastic bags having baffles inside. These pockets, preferably elongated, are placed vertically and fed from the top and taken from the bottom.
- the heating and cooling of the modules can be provided by a support plate, which on one side will receive the disposable elements and the other side will be in contact with a refrigeration or heating element.
- the lysis buffer will be cooled by passage through an appropriate cooling system.
- the dialyzer itself can be used as a heat exchanger between the blood and the lysis buffer passing through it, without the need for other devices. These heat exchanges allow a special treatment of red blood cells.
- the various modules placed on these plates may receive a cover and a coating which will maintain temperatures preferably at 4 ° C and 37 ° C.
- the washing element can take different forms; it will preferably be of the separator bowl type, it can also be reused to perform a washing after treatment of the suspension.
- the washing element is, in principle, a tank having a symmetry of revolution and consisting of two envelopes in trunk of concentric cones, the separation chamber proper being the space between the two conical surfaces.
- One of the peculiarities of the separating bowl is that it is filled at its base and at its periphery; any product introduced, if it is less dense than those already in the separation chamber, must therefore circulate against the direction of sedimentation.
- the separate components of the introduced product are organized in concentric rings which are concentrated by the gradual decrease in their diameter, and decrease in their height by the taper of the separation chamber.
- the different fluids circulate and go to this bowl thanks to a peristallic pump and eight pneumatic clamps.
- An air detector, two optical sensors and two coding wheels placed, one on the axis of the pump, and the other on the axis of the centrifuge, allow the taking of information necessary for the management of the '' all the peripherals that are the pump, the centrifuge and the clamps.
- Figure 1 is a general diagram of the disposable device;
- Figure 2 is a diagram of the separator bowl.
- the lysis-resealing device shown in FIG. 1 comprises a lysis unit A and a resealing unit B.
- the lysis unit A consists of an evaporator which is in contact with a metal plate (1) made of stainless steel having the shape of the elements of the disposable kit.
- a second refrigerated metal plate or simply an insulating material articulated on the first encloses the disposable kit in a minimum refrigerated volume. This casing thus constituted, moreover imposes on the various pockets and tubes, their maximum volume.
- This metal plate (1) comprises two elements allowing the arrival (2) and the departure (3) of the lysis buffer, the supply system of which is not shown, but consists essentially of a pump, a circuit for refrigeration and a feed tank.
- the part called kit to single use, of this lysis module On the plate (1) is removably attached, the part called kit to single use, of this lysis module.
- This part is composed by moving from the blood inlet to the outlet of the treated blood: a perforator (4) followed by a PVC tubing (5) which opens into a special pocket welded in the form of a serpentine (6 ), and playing the role of heat exchanger; a coil made of a 1/8 OD INOX tube of 1 to 1.5 m could be used instead of the PVC bag in the form of a coil, for heat exchanges with the blood.
- this exchanger is itself connected to a tube (7) which is connected by a special male luer to the arterial inlet (8) of the dialysis cartridge (9).
- a tube (12) leads to the top of a 600 ml PVC bag (11) which serves as a buffer volume, this tube is joined by another at a "Y "(13), between the outlet of the dialyzer (10) and the" delay "pocket (11).
- a last tube (14) leads from the bottom of this pocket to the outlet of the module.
- the lysis buffer input of the dialyzer consists of a tube passing through a peristaltic pump and leading to an exchanger produced by a non-disposable metal coil attached to the evaporator.
- the outlet of the dialyzer is a simple tube leading to a reservoir.
- the elements to be cooled are therefore generally of two types, on the one hand the disposable plastic kit (PVC, polycarbonate) and the metallic reusable kit both in close contact with the temperature-regulated metal plate, and d on the other hand the fluids (blood, lysis buffer, solution of active principle) which circulate and remain in the kit in contact with which they acquire the desired temperature.
- the lysis module also includes a pump tubing
- this tubing is connected to the tubing (7). Two levels are therefore possible for bringing the active substance and the red blood cells into contact, before and immediately after lysis.
- a peristaltic pump (16) which is managed by a set of controls like the other peristaltic pumps of the device, the pump (17) placed on the tubing (18) which connects to the "Y" (13) is essentially intended to purge the dialysis coil (9), this pump is like the previous one, managed by the central control unit.
- the supply of active principle by the tubing (15) can be carried out either by hand, or by means of a pump which is not shown.
- Resealing module B is also made up of a metal box (20), fitted with a door (not shown) which closes on a disposable kit, this metal box which, in contact with a heat source, will maintain 37 ° of the module in question.
- the disposable kit is composed by moving from the blood inlet at 4 degrees to the outlet for the warmed blood, a tube (14) coming directly from the "4 degrees" module, and which allows the preheating of the blood. This tubing temporarily leaves the module to pass into the body of a blood pump (21), before being connected to an identical heat exchanger (22) to that used in the 4-degree module.
- This pocket has two opposite access tubes (27 and 28), this allowing the first blood to enter, to also be the first out, it is identical to the "delay" pocket of the "4 degrees” module.
- the supply of the resealing solution carried out via the tubing (25) and the pump (30) is also controlled like the previous peristaltic pumps to the central control unit.
- the set of tubes of the four pockets (6) (11) (22) and (26) and the dialysis coil (9) which are the elements in contact with the suspension of red blood cells, are removably placed in the two resealing units, and can therefore be either re-sterilized, or discarded after use.
- the temperature pockets are made of PVC, and consist of two almost rectangular and identical PVC sheets welded together in the form of a coil. This coil leads from a PVC tube (5) located on the top of the pocket, to a second (7), which is welded to the bottom of the pocket.
- a PVC tube (5) located on the top of the pocket
- a second (7) which is welded to the bottom of the pocket.
- the maximum distance between the internal faces of the pocket will be imposed and of the order of a few tenths of mm. In this way, the volume of the exchanger will be small (from 10 to 20 ml) and the surface in contact with the plate (1) at 4 degrees will be maximum.
- the dialysis cartridge (9) has a parallelepipedal housing made of rigid plastic. This box is separated into two compartments by semi-permeable membranes, each of these compartments has two inlet-outlet tubes. One of the compartments is crossed by blood, the other by the lysis buffer. The assembly of this element in the module is done in such a way that the blood circulates from the bottom upwards in order to ensure a natural purge of the blood compartment.
- the dialysis cartridge can also be of the "hollow fiber” type, where the two compartments are formed for the blood compartment, from the interior of hollow fibers (made of semi-permeable materials) and for the lysis buffer compartment, volume outside the fibers and inside the rigid case containing these fibers.
- the dialysis outlet buffer pocket (11) is a transfer pocket of 600 ml of maximum volume, enclosed in a volume of approximately 500 ml in which it increases in volume during its filling. It is special in that the supply and drain turbulides are both mounted on a small side of the pocket, but in opposite directions. For a vertical position of the pocket, the first blood entered (from the top) will also be the first out (from the bottom).
- Figure 2 shows the section of the washing unit, the description of this repair bowl will not be given in detail since it is a product which may be commercially available, and which has been adapted for the present use.
- the separator bowl (41) in principle consists of two rigid envelopes in concentric truncated cones (42) and (43).
- the first is external (42), the second (43) placed on the same axis is included in the previous one.
- the separation chamber (44) is the space between the two conical surfaces.
- This bowl is provided with an injector system (45) and a collecting system (46), separated from the separation chamber by a rotating joint (47) at the top of the two truncated cones.
- the reservoir during the separation of the cells from the introduced suspension is rotated by a centrifuge, the injector and collector system is itself held by two articulated arms in the closed position.
- the injector (45) by its connection to a network of tubes, allows the introduction into the separator (44) of the suspension of cells to be separated, or when the bowl stops emptying the latter.
- the collector is also connected to a network, which is reduced to a tube which joins a waste bag.
- the solid elements of the suspension are gradually concentrated by centrifugation towards the outside of the chamber (44).
- a detection system previously calibrated before centrifugation allows when the concentration of red blood cells has reached a determined volume, and / or when the red blood cells have been washed properly, to obtain a suspension of red blood cells having the desired characteristics.
- the separation of the red cells is carried out during the first washing, called washing I, and allows the treatment of the blood, before the step of the reversible lysis of the red cells and their resealing.
- Washing I carried out on a whole blood unit comprises the following stages: - deplasmatization
- a cell suspension of approximately 40% hematocrit is prepared by adding physiological saline from an erythrocyte concentrate, this automatically and simultaneously with the introduction of the erythrocyte concentrate into the bowl, by alternating a quantity of water and blood in a proportion calculated by the machine so as to obtain 40% hematocrit.
- the diluted pellet is introduced into the bowl described in Figure 2 until optical detection or emptiness of the pocket, a volume of about 480 cc, this at a blood pump flow of 100 cc / min (adjustable from 0 to 250 ml / min) and a speed of rotation of the centrifuge of 6000 rpm.
- the supernatant solution is collected in a 5 liter waste bag. It is during this step that the hematocrit is empirically determined by stopping the filling of the separator at a determined level of the supernatant / cell interface (42 ml), this under precise flow and centrifugation conditions.
- the red cells are washed by introducing a programmed volume of 9% NaCl solution into the bowl, at a variable rate, under the control of the optics of the tubing.
- the flow rate of the pump is controlled in such a way that the liquid leaving the bowl is at a hematocrit of the order of 1%, allowing the elimination of the "buffy coat” while minimizing the loss of red blood cells.
- This step involves the completion of deplasmatization, as well as the elimination of platelets and white blood cells.
- the blood is now in the form of a suspension of "pure" red blood cells in the washing solution, the suspension in IHP solution is carried out, this by repeating (four times) the following manipulation: - a small volume of IHP is introduced into the bowl (of the order of
- the bowl can be emptied into a transfer bag (150 ml / min).
- the volume of blood to be treated is not sufficient to obtain a 72% hematocrit before leukoreduction in the separator (265 cc bowl), that is to say if the volume of red blood cells is less than 191 ml, the machine will go into alarm (air detection). The user will have in this situation the choice between three alternatives:
- Washing I is then finished and the dialysis phase can begin.
- Example II Lysis and resealing step
- This lysis and resealing phase takes place after washing I and is therefore intended for a suspension of red blood cells (70%) in an IHP solution of variable volume, from this minimum 265 to approximately 1.3 liters.
- This suspension will undergo the following operations: - lowering the temperature to 4 ° C
- the suspension of red cells from washing I is driven by a peristaltic pump (16) through a heat exchanger (6) where its temperature drops to 4 ° C.
- This flow rate is adjustable from 0 to 32 cc / min in steps of 1 ml / min, and determines the transit time of the blood in the dialyzer (9) for a given dead volume of the blood compartment).
- the temperature is adjustable from 1 ° C to room temperature.
- This pumping operation is carried out continuously until the pump inlet air detector is activated, indicating the emptiness of the blood bag to be treated. At this time, and in order to allow the emptying, even partial, of the heat exchanger, then of the dialysis cartridge, sterile air will be pumped for a fixed volume.
- the red blood cells once cooled in the heat exchanger (suspended in the IHP solution) pass through the blood compartment of a dialyzer at the rate imposed by the programming of the user.
- the temperature of the dialyzer is controlled (4 ° C).
- Trans-membrane pressure is measured.
- the flow rate of the lysis buffer pump (not shown) is regulated so as to maintain the trans-membrane pressure constant and at the desired level, from 0 to 300 mmHg.
- the lysis buffer is itself maintained at 4 ° C by passage through a non-disposable heat exchanger.
- the cell suspension obtained is mixed by means of the tubing (17) with a solution of ATP in a proportional manner adjustable from 1/20 th to 1/5 th (preset ratio 1/10), then left waiting for 15 minutes maximum (delay adjustable from 0 to 20 min) in the pocket (11).
- the pump (17) is responsible for conveying the ATP solution, its flow range extends from 0 to 16 ml / min. After that, the suspension is pumped at a flow rate adjustable from 0 to 32 ml / min in steps of 1 ml / min, and brought to 37 ° C by passage through a heat exchanger.
- the pump (21) located after the exchanger, so as to work on a portion of tubing which is not stiffened by too low a temperature. Then in proportion to the blood flow and in a ratio of 1/5 th to 1/20 th, the resealing product is mixed in the bag (26) with the blood reheated to 37 degrees after passage through the reheating bag (22).
- a peristaltic pump is used for this purpose, (21), its flow range extends from 0 to 16 ml / min.
- the final stage is a waiting phase for the product obtained, in order to obtain complete resealing of the red cells.
- the red cell suspension is kept for 15 to 30 min at a temperature of 37 ° C. in the 600 ml bag (26) approximately. After that washing II can then be carried out.
- Example III Washing of the red cells after resealing
- the object of the second washing is to wash and resuspend in plasma the cell suspension obtained after the lysis and resealing phase.
- the following stages compose it:
- the suspension of cells treated by dialysis is introduced into the bowl already used for washing I at a flow rate of 100 cc / min, diluted with physiological water in a ratio of 1: 2 and a speed of rotation of the centrifuge of 5000 rpm.
- This phase is stopped after a volume of approximately 1 1 has been introduced, or after detection of air in the supply tube of the bowl has occurred, a sign of the emptiness of the bag.
- air detection the question is asked, either to start washing, or to wait for the availability of other blood to be washed.
- Washing can then begin by introducing into the bowl a programmed volume of 9% NaCl solution, at a variable rate and for a centrifugation speed of 6000 rpm, under the control of the optics. the tubing.
- the pump flow is controlled in such a way that the liquid leaving the bowl is at a maximum hematocrit of the order of
- the centrifuge is then stopped, then restarted immediately, so as to homogenize the suspension solution of the red blood cells, before recommencing for a determined volume the introduction of physiological saline. Three washing steps with 500 ml of physiological water are thus carried out.
- This stop and restart phase of the centrifuge is repeated a second time, but only for two stages of approximately 100 ml, the physiological saline being replaced by plasma.
- Washes I and II can correspond to a series of cycles (one or more), a cycle corresponding to a set of phases and stages.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/170,352 US5589389A (en) | 1991-07-03 | 1992-07-02 | Apparatus for causing medicinal products to penetrate into red blood cells |
JP50201593A JP3148239B2 (ja) | 1991-07-03 | 1992-07-02 | 医薬品を赤血球に浸透させるための装置 |
EP92915621A EP0679101B1 (fr) | 1991-07-03 | 1992-07-02 | Appareil pour faire penetrer des medicaments dans des globules rouges |
DE69218265T DE69218265T2 (de) | 1991-07-03 | 1992-07-02 | Apparat zur einbringung von medikamenten in rote blutkörperchen |
NO934899A NO306327B1 (no) | 1991-07-03 | 1993-12-29 | Apparat for innföring av medikamenter i röde blodceller |
FI935940A FI935940A (fi) | 1991-07-03 | 1993-12-30 | Anordning foer att infoera medicin i roeda blodkroppar |
GR970401012T GR3023360T3 (en) | 1991-07-03 | 1997-05-09 | Apparatus for delivering drugs into red blood corpuscles. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR91/08302 | 1991-07-03 | ||
FR9108302A FR2678512B1 (fr) | 1991-07-03 | 1991-07-03 | Machine a internaliser. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993000940A1 true WO1993000940A1 (fr) | 1993-01-21 |
Family
ID=9414655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1992/000623 WO1993000940A1 (fr) | 1991-07-03 | 1992-07-02 | Appareil pour faire penetrer des medicaments dans des globules rouges |
Country Status (13)
Country | Link |
---|---|
US (1) | US5589389A (fr) |
EP (1) | EP0679101B1 (fr) |
JP (1) | JP3148239B2 (fr) |
AT (1) | ATE149846T1 (fr) |
CA (1) | CA2112685A1 (fr) |
DE (1) | DE69218265T2 (fr) |
DK (1) | DK0679101T3 (fr) |
ES (1) | ES2098519T3 (fr) |
FI (1) | FI935940A (fr) |
FR (1) | FR2678512B1 (fr) |
GR (1) | GR3023360T3 (fr) |
NO (1) | NO306327B1 (fr) |
WO (1) | WO1993000940A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2873925A1 (fr) * | 2004-08-05 | 2006-02-10 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0882448B1 (fr) * | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Méthode d'encapsulation d'agents biologiquement actifs dans des erythrocytes et appareil |
EP2258847B2 (fr) | 2002-08-05 | 2020-07-01 | Silence Therapeutics GmbH | Autres nouvelles formes de molécules d'ARN interférant |
FR2884717B1 (fr) * | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
CA2715379A1 (fr) * | 2008-02-13 | 2009-08-20 | Erytech Pharma | Formulation et procede pour la prevention et le traitement de manifestation squelettique de la maladie de gaucher |
FR2928270B1 (fr) * | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
FR2940087B1 (fr) | 2008-12-18 | 2011-05-06 | Lab Francais Du Fractionnement | Erythrocytes contenant du facteur viii, preparation et utilisations. |
IT1399590B1 (it) * | 2010-04-26 | 2013-04-26 | Erydel Spa | Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti |
AU2013237419B2 (en) | 2012-03-21 | 2016-04-28 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (AML) |
FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
EP2813234A1 (fr) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition d'érythrocytes encapsulant phenylalanine hydroxylase et l'emploi thérapeutique |
WO2017041051A1 (fr) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Administration intracellulaire de biomolécules à des cellules comprenant une paroi cellulaire |
IT202100023375A1 (it) * | 2021-09-09 | 2023-03-09 | Yang Shunfa | Dispositivo per la produzione di vescicole bioingegnerizzate dedicate e metodo correlato |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3399536A (en) * | 1966-02-02 | 1968-09-03 | Siemens Ag | Device for varying the blood temperature |
US4327710A (en) * | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
FR2529463A1 (fr) * | 1982-07-05 | 1984-01-06 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
US4668214A (en) * | 1986-06-09 | 1987-05-26 | Electromedics, Inc. | Method of washing red blood cells |
EP0292076A1 (fr) * | 1987-05-22 | 1988-11-23 | Medistad Holland B.V. | Dispositif pour chauffer le sang |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839204A (en) * | 1972-04-27 | 1974-10-01 | Gen Electric | Integral blood heat and component exchange device and two flow path membrane blood gas exchanger |
US3853479A (en) * | 1972-06-23 | 1974-12-10 | Sherwood Medical Ind Inc | Blood oxygenating device with heat exchanger |
US4517080A (en) * | 1980-06-18 | 1985-05-14 | The United States Of America As Represented By The Secretary Of Agriculture | Apparatus for encapsulating additives in resealed erythrocytes |
-
1991
- 1991-07-03 FR FR9108302A patent/FR2678512B1/fr not_active Expired - Fee Related
-
1992
- 1992-07-02 AT AT92915621T patent/ATE149846T1/de not_active IP Right Cessation
- 1992-07-02 CA CA002112685A patent/CA2112685A1/fr not_active Abandoned
- 1992-07-02 DK DK92915621.4T patent/DK0679101T3/da active
- 1992-07-02 WO PCT/FR1992/000623 patent/WO1993000940A1/fr active IP Right Grant
- 1992-07-02 ES ES92915621T patent/ES2098519T3/es not_active Expired - Lifetime
- 1992-07-02 EP EP92915621A patent/EP0679101B1/fr not_active Expired - Lifetime
- 1992-07-02 DE DE69218265T patent/DE69218265T2/de not_active Expired - Fee Related
- 1992-07-02 US US08/170,352 patent/US5589389A/en not_active Expired - Fee Related
- 1992-07-02 JP JP50201593A patent/JP3148239B2/ja not_active Expired - Fee Related
-
1993
- 1993-12-29 NO NO934899A patent/NO306327B1/no not_active IP Right Cessation
- 1993-12-30 FI FI935940A patent/FI935940A/fi unknown
-
1997
- 1997-05-09 GR GR970401012T patent/GR3023360T3/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3399536A (en) * | 1966-02-02 | 1968-09-03 | Siemens Ag | Device for varying the blood temperature |
US4327710A (en) * | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
FR2529463A1 (fr) * | 1982-07-05 | 1984-01-06 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
US4668214A (en) * | 1986-06-09 | 1987-05-26 | Electromedics, Inc. | Method of washing red blood cells |
EP0292076A1 (fr) * | 1987-05-22 | 1988-11-23 | Medistad Holland B.V. | Dispositif pour chauffer le sang |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2873925A1 (fr) * | 2004-08-05 | 2006-02-10 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
WO2006016247A3 (fr) * | 2004-08-05 | 2006-06-22 | Erytech Pharma | Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges |
CN101031339B (zh) * | 2004-08-05 | 2012-07-18 | 爱瑞泰克药物公司 | 将活性成份掺入红细胞的裂解/再封方法和装置 |
KR101332733B1 (ko) | 2004-08-05 | 2013-11-25 | 에리테끄 파르마 | 적혈구에 활성 성분을 내재화시키는 용해/재봉합 방법 및 장치 |
Also Published As
Publication number | Publication date |
---|---|
FR2678512B1 (fr) | 1995-06-30 |
DE69218265T2 (de) | 1997-08-14 |
FI935940A0 (fi) | 1993-12-30 |
EP0679101A1 (fr) | 1995-11-02 |
DK0679101T3 (da) | 1997-09-22 |
CA2112685A1 (fr) | 1993-01-21 |
ATE149846T1 (de) | 1997-03-15 |
DE69218265D1 (de) | 1997-04-17 |
FR2678512A1 (fr) | 1993-01-08 |
EP0679101B1 (fr) | 1997-03-12 |
GR3023360T3 (en) | 1997-08-29 |
ES2098519T3 (es) | 1997-05-01 |
NO934899D0 (no) | 1993-12-29 |
FI935940A (fi) | 1994-02-17 |
JP3148239B2 (ja) | 2001-03-19 |
NO306327B1 (no) | 1999-10-25 |
NO934899L (no) | 1994-03-01 |
JPH06509250A (ja) | 1994-10-20 |
US5589389A (en) | 1996-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0679101B1 (fr) | Appareil pour faire penetrer des medicaments dans des globules rouges | |
US7918350B2 (en) | Separation apparatus and method | |
US5217627A (en) | System and method for processing biological fluid | |
EP0556303B1 (fr) | Systeme de traitement de liquides biologiques | |
FR2716626A1 (fr) | Procédé de traitement d'un fluide biologique, notamment en aphérèse, et système à y utiliser. | |
CH685922A5 (fr) | Dispositif automatise de traitement d'un fluide biologique et son utilisation. | |
EP0643582A1 (fr) | Procede d'obtention d'un surnageant de thrombocytes actives | |
ITTO930642A1 (it) | Rimozione di fluidi non desiderati da prodotti sanguigni trattati. | |
JP2006513019A (ja) | 成分への生物学的流体の連続的分離のための改良型方法及び装置 | |
US10980933B2 (en) | System and method for platelet removal during mononuclear cell collection | |
CA2576498C (fr) | Procede d'autotransfusion et dispositif d'autotransfusion a separation de phases et concentration a poches amovibles | |
US20210154390A1 (en) | Low volume extracorporeal photopheresis systems and methods | |
AU2004312012B8 (en) | Separation apparatus and method | |
EP3990048B1 (fr) | Système et procédé de traitement de liquide hémorragique pour de l'autotransfusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992915621 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2112685 Country of ref document: CA Ref document number: 935940 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08170352 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992915621 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992915621 Country of ref document: EP |